The long-acting β-adrenergic agonist controversy in asthma: Troublesome times!

Journal of Allergy and Clinical Immunology

Volumn 130, Issue 6, 2012, Pages 1256-1259

  Szefler, Stanley J ^a   Busse, William W ^b  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Asthma; asthma control; asthma guidelines; inhaled corticosteroids (ICSs); long acting adrenergic agonists (LABAs)

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FENOTEROL; LONG ACTING BETA ADRENERGIC AGONIST; SALMETEROL; UNCLASSIFIED DRUG;

ASTHMA; BRONCHODILATATION; DISEASE EXACERBATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW;

EID: 84870279125     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2012.10.021     Document Type: Editorial

References (36)

1. National Heart, Lung, and Blood Institute. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma - full report 2007. Available at: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed September 22, 2012.
2. B.A. Chowdhury, S.M. Seymour, and M.S. Levenson Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma N Engl J Med 364 2011 2473 2475
3. A.P. Greening, P.W. Ind, M. Northfield, and G. Shaw Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group Lancet 344 1994 219 224
4. Global Initiative for Asthma: National Heart, Lung and Blood Institute. Global strategy for asthma management and prevention. Available at: http//www.ginasthma.com. Accessed September 22, 2012.
5. P.D. Stolley, and R. Schinnar Association between asthma mortality and isoproterenol aerosols: a review Prev Med 7 1978 519 538
6. N. Pearce, and M.J. Hensley Epidemiologic studies of beta agonists and asthma deaths Epidemiol Rev 20 1998 173 186
7. J.M. Drazen, E. Israel, H.A. Boushey, V.M. Chinchilli, J.V. Fahy, and J.E. Fish Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network N Engl J Med 335 1996 841 847
8. M.R. Sears Short-acting beta-agonist research: a perspective Can Respir J 5 suppl A 1998 54A 59A
9. S. Suissa, P. Ernst, J.F. Bolvin, R.I. Horwitz, B. Habbick, and D. Cockcroft A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists Am J Respir Crit Care Med 1469 1994 604 610
10. National Asthma Education and Prevention Program Expert panel report-2: guidelines for the diagnosis and management of asthma 1997 National Institutes of Health Bethesda
11. S. Pedersen, and P.O. O'Byrne Combination inhaled corticosteroid and long-acting β2-agonist use and severe asthma exacerbations J Allergy Clin Immunol 129 2012 1280 1281
12. H.S. Nelson, S.T. Weiss, E.R. Bleecker, S.W. Yancey, and P.M. Dorinsky The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol Chest 129 2006 15 26
13. B.A. Chowdhury, and G. Dal Pan The FDA and safe use of long-acting beta-agonists in the treatment of asthma N Engl J Med 362 2010 1169 1171
14. W. Castle, R. Fuller, J. Hall, and J. Palmer Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment BMJ 306 1993 1034 1037
15. J.L. Brozek, M. Kraft, J.A. Krishnan, M.M. Cloutier, S.C. Lazarus, and J.T. Li Long-acting beta2-agonist step-off in patients with controlled asthma: systematic review with meta-analysis Arch Intern Med 2012 1 11 [Epub ahead of print]
16. E. Bateman, H. Nelson, J. Bousquet, K. Kral, L. Sutton, and H. Ortega Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events Ann Intern Med 149 2008 33 42
17. M.R. Sears, A. Ottosson, F. Radner, and S. Suissa Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials Eur Respir J 33 2009 21 32
18. P. Ernst, A. McIvor, F.M. Ducharme, L.P. Boulet, M. FitzGerald, and K.R. Chapman Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids Ann Intern Med 145 2006 692 694
19. S.R. Salpeter, N.S. Buckley, T.M. Ormiston, and E.E. Salpeter Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths Ann Intern Med 144 2006 904 912
20. G.J. Rodrigo, and J.A. Castro-Rodriguez Safety of long-acting beta agonists for the treatment of asthma: clearing the air Thorax 67 2012 342 349
21. J.M. Drazen, and P.M. O'Byrne Risks of long-acting beta-agonists in achieving asthma control N Engl J Med 360 2009 1671 1672
22. L.J. Akinbami, J.E. Moorman, C. Bailey, H.S. Zahran, M. King, and C. Johnson Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. National Center for Health Care Statistics Data Brief May, 2012 Centers for Disease Control and Prevention; No. 94 Atlanta
23. S.J. Szefler Advancing asthma care: the glass is only half full! J Allergy Clin Immunol 128 2011 485 494
24. C.M. Chan, and A.F. Shorr Black clouds and black boxes: comment on "Long-acting beta2-agonist step-off in patients with controlled asthma" Arch Intern Med 1 2012 [Epub ahead of print]
25. P.M. O'Byrne, H. Bisgaard, P.P. Godard, M. Pistolesi, M. Palmqvist, and Y. Zhu Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma Am J Respir Crit Care Med 171 2005 129 136
26. R.F. Lemanske Jr., and W.W. Busse The US Food and Drug Administration and long-acting beta2-agonists: the importance of striking the right balance between risks and benefits of therapy? J Allergy Clin Immunol 126 2010 449 452
27. H.W. Kelly, A.L. Sternberg, R. Lescher, A.L. Fuhlbrigge, P. Williams, and R.S. Zeiger Effect of inhaled glucocorticoids in childhood on adult height N Engl J Med 376 2012 904 912
28. M.R. Sears Epidemiology of asthma exacerbations J Allergy Clin Immunol 122 2008 662 668
29. N.A. Hanania, O. Alpan, D.L. Hamilos, J.J. Condemi, I. Reyes-Rivera, and J. Zhu Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial Ann Intern Med 154 2011 573 582
30. S.P. Peters, S.J. Kunselman, N. Icitovic, W.C. Moore, R. Pascual, and B.T. Ameredes Tiotropium bromide step-up therapy for adults with uncontrolled asthma N Engl J Med 363 2010 1715 1726
31. H.A. Kerstjens, M. Engel, R. Dahl, P. Paggiaro, E. Beck, and M. Vandewalker Tiotropium in asthma poorly controlled with standard combination therapy N Engl J Med 367 2012 1198 1207
32. E.H. Bel Tiotropium for asthma-promise and caution N Engl J Med 367 2012 1257 1259
33. A. Thomas, R.F. Lemanske Jr., and D.J. Jackson Approaches to stepping up and stepping down care in asthmatic patients J Allergy Clin Immunol 128 2011 915 926
34. W.J. Calhoun, B.T. Ameredes, T.S. King, N. Icitovic, E.R. Bleeker, and M. Castro Comparison of physician-based, biomarker-based, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized trial JAMA 308 2012 987 997
35. J. Corren, R.F. Lemanske, N.A. Hanania, P.E. Korenblat, M.V. Parsey, and J.R. Arron Lebrikizumab treatment in adults with asthma N Engl J Med 365 2011 1088 1098
36. S.J. Szefler, V.M. Chinchilli, E. Israel, L.C. Denlinger, R.F. Lemanske, and W. Calhoun Key observations from the NHLBI Asthma Clinical Research Network Thorax 67 2012 450 455